PM
XLRN

Parametrica Management’s Acceleron Pharma XLRN Stock Holding History

Parametrica Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,288
Closed -$360K – 360
2018
Q3 		$360K Buy
6,288
+643
+11% +$31.6K 0.79% 31
2018
Q2 		$274K Buy
+5,645
New +$206K 1.3% 29

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Parametrica Management's XLRN Position: Q4 2018 in Review

Parametrica Management sold out of Acceleron Pharma (XLRN) in Q4 2018, closing a stake of 6,288 shares — an estimated $360K sold.

Parametrica Management first reported a position in XLRN in Q2 2018 and held it in 2 quarters. The position peaked at $360K in Q3 2018. 162 funds tracked by Wall St. Rank hold XLRN as of Q4 2018.

  • Parametrica Management reported no remaining Acceleron Pharma position as of Q4 2018 after selling out during the quarter.
  • Parametrica Management sold 6,288 Acceleron Pharma shares in Q4 2018, an estimated $360K.
  • Parametrica Management first reported a position in Acceleron Pharma in Q2 2018 and held it in 2 quarters.
  • Parametrica Management's Acceleron Pharma position peaked at $360K in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2018.

Based on Parametrica Management's 13F filing for Q4 2018, filed 12 Feb 2019.